TTR and cancer: Multiple strategies are available to target CTS, such as chemical inhibitors including CA074, odanacatib (MK-0822), KGP94, CLIK-148, and CLIK-195, which are highly specific and efficient; and CTS antibodies to target CTS secretion, which hold considerable potential for cancer treatment [12,129,177,180,184].